The Multiple Myeloma Research Foundation (MMRF) is a charitable organization dedicated to multiple myeloma, an incurable blood cancer. The MMRF runs as if it were a for-profit business, expecting high returns from the money the organization raises from donors.[1]
History
editMMRF was founded in 1998 by twin sisters Kathy Giusti and Karen Andrews, following Kathy's diagnosis with multiple myeloma. Giusti, a pharmaceutical company executive and Harvard Business School Alum, wanted to encourage researchers to develop treatments for multiple myeloma by using business models rather than academic models of drug development.[1]
About The MMRF
editMMRF is a private funder of multiple myeloma research, having raised over $120 million since its inception to contribute funding to more than 120 laboratories worldwide.[2] MMRF funding contributes to diverse research strategies to yield long-, mid-, and short-term results in an effort to deliver better treatments to patients faster: basic science programs to better understand the disease and identify new druggable targets through genomics and proteomics research; validation programs to prioritize new compounds and combinations based on key targets; and clinical trials conducted at a number of myeloma centers.[citation needed]
In 2009, the MMRF funded research into 30 compounds at the pre-clinical stage.[3] By 2013 it had raised more than $250 million and its work has helped gain approval of six new drugs to treat the disease.[4]
See also
editNotes
edit- ^ a b Groopman, Jerome (January 28, 2008). "Buying a Cure.(Kathy Giusti's Multiple Myeloma Research Foundation)". The New Yorker. Retrieved 16 December 2009.
- ^ "Harvard Business School Awards MMRF Founder, CEO with Alumni Achievement Award". Reuters (Business wire). 2009-10-22. Archived from the original on 2016-03-03. Retrieved 16 December 2009.
- ^ Duxbury, Sarah (December 8, 2006). "Foundations move in where VCs fear to tread". San Francisco Business Times. Retrieved 16 December 2009.
- ^ "A Mission with Precision", Forbes Magazine, December 3, 2013